Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in the Phase II LEGATO-HD trial to treat HD. Laquinimod did meet the secondary endpoint of reducing brain atrophy vs. placebo.

The double-blind, international trial enrolled 352 patients. Partner Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) will submit the data for presentation at a medical meeting...